|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prostate cancer in Asia:A collaborative report显示文摘The incidence of prostate cancer(PCa)within Asian population used to be much lower than in the Western population;however,in recent years the incidence and mortality rate of PCa in some Asian countries have grown rapidly.This collaborative report summarized the latest epidemiology information,risk factors,and racial differences in PCa diagnosis,current status and new trends in surgery management and novel agents for castration-resistant prostate cancer.We believe such information would be helpful in clinical decision making for urologists and oncologists,health-care ministries and medical researchers. | Rui Chen Shancheng Ren 无 Ming Kwong Yiu Ng Chi Fai Wai Sam Cheng Lap Hong Ian Seiji Naito Tadashi Matsuda Elijah Kehinde Ali Kural Jason Yichun Chiu Rainy Umbas Qiang Wei Xiaolei Shi Liqun Zhou Jian Huang Yiran Huang Liping Xie Lulin Ma Changjun Yin Danfeng Xu Kexin Xu Zhangqun Ye Chunxiao Liu Dingwei Ye Xin Gao Qiang Fu Jianquan Hou Jianlin Yuan Dalin He Tiejun Pan Qiang Ding Fengshuo Jin Benkang Shi Gongxian Wang Xiuheng Liu Dongwen Wang Zhoujun Shen Xiangbo Kong Wanhai Xu Yaoliang Deng Haibo Xia Alexa NCohen Xu Gao Chuanliang Xu Yinghao Sun | 2014 | Asian Journal of Urology2014，1，1： | 13 |
| 2 | Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0-10.0 ng/mL:Results from the Chinese Prostate Cancer Consortium显示文摘Objective:To test the diagnostic performance of percent free prostate-specific antigen(%fPSA)in predicting any prostate cancer(PCa)and high-grade prostate cancer(HGPCa)in a retrospective multi-center biopsy cohort with a PSA level of 4.0e10.0 ng/mL in China.Methods:Consecutive patients with a PSA of 4.0-10.0 ng/mL who underwent transrectal ultrasound-guided biopsy were enrolled at 16 Chinese medical centers from January 1st,2010 to December 31st,2013.Total and free serum PSA determinations were performed using three types of electro-chemiluminescence immunoassays recalibrated to the World Health Organization(WHO)standard.The diagnostic accuracy of PSA,%fPSA,and %fPSA in combination with PSA(%fPSA t PSA)was determined using the area under the receiver operating characteristic(ROC)curve(AUC).Results:A total of 2310 consecutive men with PSA levels between 4.0 and 10.0 ng/mL were included,and the detection rate of PCa was 25.1%.The AUC of%fPSA and %fPSA t PSA in predicting any PCa was superior to PSA alone in men aged≥60 years(0.623 vs.0.534,p<0.0001)but not in men aged 40e59 years(0.517 vs.0.518,p=0.939).Similar result was yield in predicting HGPCa.Conclusion:In a clinical setting of Chinese men with 4.0e10.0 ng/mL PSA undergoing initial prostate biopsy,adding %fPSA to PSA can moderately improve the diagnostic accuracy for any PCa and HGPCa compared with PSA alone in patients≥60 but not in patients aged 40-59 years. | Rui Chen Liping Xie Xiaobing Cai Yiran Huang Liqun Zhou Lulin Ma Xu Gao Chuanliang Xu Shancheng Ren Pengfei Shao Danfeng Xu Kexin Xu Zhangqun Ye Chunxiao Liu Dingwei Ye Li Lu Qiang Fu Jianquan Hou Jianlin Yuan Dalin He Tie Zhou Fubo Wang Biming He Yinghao Sun | 2015 | Asian Journal of Urology2015，2，2： | 8 |
| 3 | Adjuvant hormone therapy after radical prostatectomy in highrisk localized and locally advanced prostate cancer: First multicenter, observational study in China显示文摘Objective: Potential of combined androgen blockade(CAB) has not been explored extensively in Chinese males with prostate cancer(PCa). Therefore, this study evaluated the 2-year prostate-specific antigen(PSA) recurrence rate and quality of life(Qo L) in patients with high-risk localized and locally advanced PCa receiving adjuvant hormone therapy(HT) after radical prostatectomy(RP).Methods: This prospective, multicenter, observational study conducted in 18 centers across China enrolled patients with high-risk factor(preoperative PSA>20 ng/m L or Gleason score >7) or locally advanced PCa. Different adjuvant HT were administered after RP according to investigator’s decision in routine clinical practice.Relationship of baseline and postoperative characteristics was assessed with recurrence rate. PSA recurrence rate and Functional Assessment of Cancer Therapy-Prostate(FACT-P) Qo L scores were recorded at 12 months and 24 months. Kaplan-Meier analysis was used to construct the PSA recurrence rate during follow-up.Results: A total of 189 patients(mean age: 66.9±6.5 years) were recruited, among which 112(59.3%) patients showed serum PSA>20 ng/m L preoperatively. The highest postoperative pathological advancement noticed was from clinical T2(c T2) to pathological T3(p T3)(43.9%) stage. The majority of the patients(66.1%) received CAB as adjuvant HT, for a median duration of 20.0 months. The least recurrence(15.2%) was noticed in patients treated with CAB, followed by those treated with luteinizing hormone-releasing hormone agonist(LHRHa)(16.1%), and antiandrogen(19.0%), with non-significant difference noted among the groups. None of the baseline or postoperative characteristics was related with PSA recurrence in our study. The 24-month FACT-P Qo L score of119 patients treated for >12 months showed significant improvement above baseline compared with those treated for ≤12 months.Conclusions: Adjuvant CAB therapy after RP showed reduction trend in 2-year PSA recurrence rate in highrisk Chinese patients with localized and locally advanced PCa, compared with adjuvant anti-androgens(AA) or LHRHa therapy. Further long-term therapy(>12 months) significantly improved Qo L compared to short-term HT therapy, suggesting the beneficial effect of long-term CAB therapy in improving Qo L. | Dingwei Ye Wei Zhang Lulin Ma Chuanjun Du Liping Xie Yiran Huang Qiang Wei Zhangqun Ye Yanqun Na | 2019 | Chinese Journal of Cancer Research2019，31，3： | 4 |
| 4 | A phase 3,double-blind,randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaı¨ve patients with mCRPC in China,Malaysia,Thailand and Russia显示文摘Objective:This double-blind,placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate+prednisone(abiraterone)to prednisone alone in chemotherapy-naı¨ve,asymptomatic or mildly symptomatic metastatic castrationresistant prostate cancer(mCRPC)patients from China,Malaysia,Thailand and Russia.Methods:Adult chemotherapy-naı¨ve patients with confirmed prostate adenocarcinoma,Eastern Cooperative Oncology Group(ECOG)performance status(PS)grade 0e1,ongoing androgen deprivation(serum testosterone<50 ng/dL)with prostate specific antigen(PSA)or radiographic progression were randomized to receive abiraterone acetate(1000 mg,QD)t prednisone(5 mg,BID)or placebo t prednisone(5 mg,BID),until disease progression,unacceptable toxicity or consent withdrawal.Primary endpoint was improvements in time to PSA progression(TTPP).Results:Totally,313 patients were randomized(abiraterone:n Z 157;prednisone:n Z 156);and baseline characteristics were balanced.At clinical cut-off(median follow-up time:3.9 months),80% patients received treatment(abiraterone:n Z 138,prednisone:n Z 112).Median time to PSA progression was not reached with abiraterone versus 3.8 months for prednisone,attaining 58%reduction in PSA progression risk(HR=0.418;p<0.0001).Abirateronetreated patients had higher confirmed PSA response rate(50%vs.21%;relative odds=2.4;p<0.0001)and were 5 times more likely to achieve radiographic response than prednisonetreated patients(22.9%vs.4.8%,p=0.0369).Median survival was not reached.Most common(≥10% abiraterone vs.prednisone-treated)adverse events:bone pain(7%vs.14%),pain in extremity(6%vs.12%),arthralgia(10%vs.8%),back pain(7%vs.11%),and hypertension(15%vs.14%).Conclusion:Interim analysis confirmed favorable benefit-to-risk ratio of abiraterone in chemotherapy-naı¨ve men with mCRPC,consistent with global study,thus supporting use of abiraterone in this patient population. | Dingwei Ye Yiran Huang Fangjian Zhou Keji Xie Vsevolod Matveev Changling Li Boris Alexeev Ye Tian Mingxing Qiu Hanzhong Li Tie Zhou Peter De Porre Margaret Yu Vahid Naini Hongchuan Liang Zhuli Wu Yinghao Sun | 2017 | Asian Journal of Urology2017，4，2： | 3 |
| 5 | Hot-band absorption of indocyanine green for advanced anti-stokes fluorescence bioimaging显示文摘Bright anti-Stokes fluorescence(ASF)in the first near-infrared spectral region(NIR-I,800 nm–900 nm)under the excitation of a 915 nm continuous wave(CW)laser,is observed in Indocyanine Green(ICG),a dye approved by the Food and Drug Administration for clinical use.The dependence of fluorescence intensity on excitation light power and temperature,together with fluorescence lifetime measurement,establish this ASF to be originated from absorption from a thermally excited vibrational level(hot-band absorption),as shown in our experiments,which is stronger than the upconversion fluorescence from widely-used rare-earth ion doped nanoparticles.To test the utility of this ASF NIR-I probe for advanced bioimaging,we successively apply it for biothermal sensing,cerebral blood vessel tomography and blood stream velocimetry.Moreover,in combination with L1057 nanoparticles,which absorb the ASF of ICG and emit beyond 1100 nm,these two probes generate multi-mode images in two fluorescent channels under the excitation of a single 915 nm CW laser.One channel is used to monitor two overlapping organs,urinary system&blood vessel of a live mouse,while the other shows urinary system only.Using in intraoperative real-time monitoring,such multi-mode imaging method can be beneficial for visual guiding in anatomy of the urinary system to avoid any accidental injury to the surrounding blood vessels during surgery. | Jing Zhou Xiaoxiao Fan Di Wu Jie Liu Yuhuang Zhang Zikang Ye Dingwei Xue Mubin He Liang Zhu Zhe Feng Andrey N.Kuzmin Wen Liu Paras N.Prasad Jun Qian | 2021 | Light(Science & Applications)2021，10，10： | 3 |
| 6 | Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population显示文摘Objective:To evaluate the diagnostic value of fluorescence in situ hybridization(FISH)in bladder cancer.Methods:We enrolled healthy volunteers and patients who were clinically suspected to have bladder cancer and conducted FISH tests and cytology examinations from August 2007 to December 2008.Receiver operating characteristic(ROC)curve analysis was performed and the area under curve(AUC)values were calculated for both the FISH and urine cytology tests.Results:A cohort of 988 healthy volunteers was enrolled to establish a reference range for the normal population.A total of 4807 patients with hematuria were prospectively,randomly enrolled for the simultaneous analysis of urine cytology,FISH testing,and a final diagnosis as determined by the pathologic findings of a biopsy or a surgically-excised specimen.Overall,the sensitivity of FISH in detecting transitional-cell carcinoma was 82.7%,while that of cytology was 33.4%(p<0.001).The sensitivity values of FISH for non-muscle invasive and muscle invasive bladder transitional-cell carcinoma were 81.7%and 89.6%,respectively(p=0.004).The sensitivity values of FISH for low and high grade bladder cancer were 82.6%and 90.1%,respectively(p=0.002).Conclusion:FISH is significantly more sensitive than voided urine cytology for detecting bladder cancer in patients evaluated for gross hematuria at all cancer grades and stages.Higher sensitivity using FISH was obtained in high grade and muscle invasive tumors. | Liqun Zhou Kaiwei Yang Xuesong Li Yi Ding Dawei Mu Hanzhong Li Yong Yan Jinyi Li Dongwen Wang Wei Li Yulong Cong Jiangping Gao Kewei Ma Yajun Xiao Sheng Zhang Hongyi Jiang Weilie Hu Qiang Wei Xunbo Jin Zhichen Guan Qingyong Liu Danfeng Xu Xin Gao Yongguang Jiang Weimin Gan Guang Sun Qing Wang Yanhui Liu Jianquan Hou Liping Xie Xishuang Song Fengshuo Jin Jiafu Feng Ming Cai Zhaozhao Liang Jie Zhang Dingwei Ye Lin Qi Lulin Ma Jianzhong Shou Yuping Dai Jianyong Shao Ye Tian Shizhe Hong Tao Xu Chuize Kong Zefeng Kang Yuexin Liu Xun Qu Benkang Shi Shaobin Zheng Yi Lin Shujie Xia Dong Wei Jianbo Wu Weiling Fu Zhiping Wang Jianbo Liang | 2019 | Asian Journal of Urology2019，6，1： | 2 |
| 7 | Constitutive law and fatiguecharacteristics of expanded polystyrene under uniaxialcompression 显示文摘 | Ling Jianming WuZheng Ye Dingwei | 2003 | Journal of Tongji University : NaturalScience2003，31，1： | 1 |
| 8 | Livin expressionmay be regulated by miR-198 in human prostate cancer cell lines显示文摘 | LIN YE SHENG LI DINGWEI YE | 2013 | Euro J Cancer2013，49，3： | 1 |
| 9 | Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases显示文摘基因风险分数(GRS ) 基于疾病联系风险的单个核苷酸多型性(SNP ) 是能被用来除了家庭历史为特定的疾病提供继承信息的一个增进知识的工具。然而,当计算 GRS 时,在一个特定的种族组被含有的 SNP 是否仅仅应该被使用,仍然是未知的。学习是为在 1338 个病人之中预言前列腺癌症(PCa ) 比较赛跑特定的 GRS 和 nonrace 特定的 GRS 的表演的这的目的在上海经历了前列腺活体检视,中国。赛跑特定的 GRS 与七 PCa 联系风险的 SNP 被计算在东方亚洲人(GRS7 ) 含有,并且 nonrace 特定的 GRS 基于 76 PCa 联系风险的 SNP 是计算的在至少一个种族组(GRS76 ) 含有。分别地, GRS7 和 GRS76 的工具在学习人口是 1.19 和 1.85。更高的 GRS7 和 GRS76 在 univariate 和 multivariate 分析是为 PCa 和高级 PCa 的独立预言者。GRS7 为区别 PCa (0.602 对 0.573 ) 和高级 PCa (0.603 对 0.575 ) 比 GRS76 在操作接收装置的曲线(AUC ) 下面有一个更好的区域但是没到达统计意义。有的 GRS7 一更好(多达 13% 在不同截止) 积极预兆的价值(PPV ) 比 GRS76。在结论,赛跑特定的 GRS 是更柔韧的并且当比用没被显示与东方亚洲人被联系的 SNP 计算的 GRS 在东方亚洲人预言 PCa 时,有更好的表演。 | Rong Na Dingwei Ye Jun Qi Fang Liu Xiaoling Lin Brian T Helfand Charles B Brendler Carly Conran Jian Gong Yishuo Wu Xu Gao Yaqing Chen S Lilly Zheng Zengnan Mo Qiang Ding Yinghao Sun Jianfeng Xu | 2016 | Asian Journal of Andrology2016，18，4： | 1 |
| 10 | Targeting the Neddylation Pathway to Suppress the Growth of Prostate Cancer Cells: Therapeutic Implication for the Men’s Cancer显示文摘 | Xiaofang Wang Lihui Li Yupei Liang Chunjie Li Hu Zhao Dingwei Ye Menghong Sun Lak Shin Jeong Yan Feng Shen Fu Lijun Jia Xiaomao Guo Zhen Chen | 2014 | BioMed Research International2014，，： | 1 |
| 11 | A brief review on the diagnostic and therapeutic principles of primary urethral cancer显示文摘Objective:Primary urethral carcinoma(PUC)is a rare malignant carcinoma but with limited therapeutic options.This review aims to provide an overview of the current strategies on this patient settings.Methods:Recent literature ranging from January 1987 and December 2021 was assessed through PubMed search to assess the diagnostic and therapeutic principles of PUC.Results:A complete of examination including cystoscopy,imaging,and biopsy should be conducted for these patients.Once diagnosed,the clinical decision of PUC should be made according to the tumor location,pathological pattern,and extent of the tumor.For patients with superficial and distal urethral lesions,organ sparing approaches or radical reconstructive procedures can be utilized.While for more advanced disease or nodal involvement,an optimal multimodal treatment strategy consisted of surgery and radiochemotherapy should be adopted.For patients with urothelial carcinoma of the prostate,the management including transurethral resection of the prostate followed by bacille Calmette-Guerin or radical cysto-prostatectomy should depend on the infiltration depth of PUC.Conclusion:A complete of examination is important for the diagnosis of PUC.The management of PUC should be determined by the location,pathological pattern,and extent of the tumor.More multi-institutional collaborations should be held to investigate better treatment modal-ities for PUC. | Hengchuan Su Yao Zhu Dingwei Ye | 2022 | Asian Journal of Urology2022，9，4： | 1 |
| 12 | Livin expressionmay be regulated by miR-198 in human prostate cancer cell lines显示文摘 | LIN YE SHENG LI DINGWEI YE | 2013 | Euro J Cancer2013，49，3： | 1 |
| 13 | Survival after radical cystectomy for bladder cancer:Multicenter comparison between minimally invasive and open approaches显示文摘Objective:To investigate oncological outcomes in patients with bladder cancer who underwent minimally invasive radical cystectomy(MIRC)or open radical cystectomy(ORC).Methods:We identified patients with bladder cancer who underwent radical cystectomy(RC)in 13 centers of the Chinese Bladder Cancer Consortium(CBCC).Perioperative outcomes were compared between MIRC and ORC.The influence of surgical approaches on overall survival(OS)and cancer-specific survival(CSS)in the entire study group and subgroups classified according to pathologic stage or lymph node(LN)status was assessed with the log-rank test.Multivariable Cox proportional hazard models were used to evaluate the association among OS,CSS and risk factors of interest.Results:Of 2098 patients who underwent RC,1243 patients underwent MIRC(1087 laparoscopic RC and 156 robotic-assisted RC,respectively),while 855 patients underwent ORC.No significant differences were noted in positive surgical margin rate and 90-day postoperative mortality rate.MIRC was associated with less estimated blood loss,more LN yield,higher rate of neobladder diversion,longer operative time,and longer length of hospital stay.There was no significant difference in OS and CSS according to surgical approaches(pZ0.653,and 0.816,respectively).Subgroup analysis revealed that OS and CSS were not significantly different regardless of the status of extravesical involvement or LN involvement.Multivariable Cox regression analyses showed that the surgical approach was not a significant predictor of OS and CSS.Conclusions:Our study showed that MIRC was comparable to conventional ORC in terms of OS and CSS. | Weibin Xie Junming Bi Qiang Wei Ping Han Dongkui Song Lei Shi Dingwei Ye Yijun Shen Xin Gou Weiyang He Shaogang Wang Zheng Liu Jinhai Fan Kaijie Wu Zhiwen Chen Xiaozhou Zhou Chuize Kong Yang Liu Chunxiao Liu Abai Xu Baiye Jin Guanghou Fu Wei Xue Haige Chen Tiejun Pan Zhong Tu Tianxin Lin Jian Huang | 2020 | Asian Journal of Urology2020，7，3： | 1 |
| 14 | Systematic Genome-Wide Profiles Reveal Alternative Splicing Landscape and Implications of Splicing Regulator DExD-Box Helicase 21 in Aggressive Progression of Adrenocortical Carcinoma显示文摘Alternative splicing(AS)in the tumor biological process has provided a novel perspective on carcinogenesis.However,the clinical significance of individual AS patterns of adrenocortical carcinoma(ACC)has been underestimated,and in-depth investigations are lacking.We selected 76 ACC samples from the Cancer Genome Atlas(TCGA)SpliceSeq and SpliceAid2 databases,and 39 ACC samples from Fudan University Shanghai Cancer Center(FUSCC).Prognosis-related AS events(PASEs)and survival analysis were evaluated based on prediction models constructed by machine-learning algorithm.In total,23,984 AS events and 3,614 PASEs were detected in the patients with ACC.The predicted risk score of each patient suggested that eight PASEs groups were significantly correlated with the clinical outcomes of these patients(p<0.001).Prognostic models produced AUC values of 0.907 in all PASEs’groups.Eight splicing factors(SFs),including BAG2,CXorf56,DExD-Box Helicase 21(DDX21),HSPB1,MBNL3,MSI1,RBMXL2,and SEC31B,were identified in regulatory networks of ACC.DDX21 was identified and validated as a novel clinical promoter and therapeutic target in 115 patients with ACC from TCGA and FUSCC cohorts.In conclusion,the strict standards used in this study ensured the systematic discovery of profiles of AS events using genome-wide cohorts.Our findings contribute to a comprehensive understanding of the landscape and underlying mechanism of AS,providing valuable insights into the potential usages of DDX21 for predict-ing prognosis for patients with ACC. | Wenhao Xu Aihetaimujiang Anwaier Wangrui Liu Xi Tian Wen-Kai Zhu Jian Wang Yuanyuan Qu Hailiang Zhang Dingwei Ye | 2021 | Phenomics2021，1，6： | 0 |
| 15 | 全基因组关联研究发现中国人群前列腺癌两个新易感位点9q31.2和19q13.4显示文摘0前言在全球范围内,前列腺癌的发病率和病死率存在着巨大差异。该病在西方发达国家发病率最高,在非裔美国人群病死率最高,而在亚洲人群中发病率及病死率均为全球最低,提示不同人种在前列腺癌的遗传方面存在异质性。在欧美和日本人群中,全基因组关联研究(GWAS)技术已经被用于检测前列腺癌的遗传易感性位点,但至今尚无关于GWAS检测中国人群前列腺癌易感位点的报道。 | Jianfeng Xu Zengnan Mo Dingwei Ye Meilin Wang Fang Liu Guangfu Jin Chuanliang Xu Xiang Wang Qiang Shao Zhiwen Chen Zhihua Tao Jun Qi Fangjian Zhou Zhong Wang Yaowen Fu Dalin He Qiang Wei Jianming Guo Denglong Wu Xin Gao Jianlin Yuan Gongxian Wang Yong Xu Guozeng Wang Haijun Yao Pei Dong Yang Jiao Mo Shen Jin Yang Jun Ou-Yang Haowen Jiang Yao Zhu Shancheng Ren Zhengdong Zhang Changjun Yin Xu Gao Bo Dai Zhibin Hu Yajun Yang Qijun Wu Hongyan Chen Peng Peng Ying Zheng Xiaodong Zheng Yongbing Xiang Jirong Long Jian Gong Rong Na Xiaoling Lin Hongjie Yu Sha Tao Junjie Feng Jishan Sun Wennuan Liu Ann Hsing Jianyu Rao Qiang Ding Fredirik Wiklund Henrik Gronberg Xiao-Ou Shu Wei Zheng Hongbing Shen Li Jin Rong Shi Daru Lu Xuejun Zhang Jielin Sun S Lilly Zheng Yinghao Sun | 2013 | 第二军医大学学报2013，34，4： | 0 |
| 16 | 端粒维持基因多态性与膀胱癌易感性的关系(英文)显示文摘Telomere maintenance genes play an important role in maintaining the integrity of the telomere structure that protects chromosome ends,and telomere dysfunction may lead to tumorigenesis.Genetic variation in telomere maintenance genes has been confirmed.Cumulative evidence shows that the difference of telomere length and stability among the individual depends on the genetic variants of telomere maintenance genes.Genetic variants in telomere maintenance genes may affect telomere length and stability,thus the increased cancer risk.This review intends to summarize the association of genetic variants in telomere maintenance genes with bladder cancer risk. | Chengyuan Gu Yao Zhu Dingwei Ye | 2013 | The Chinese-German Journal of Clinical Oncology2013，12，9： | 0 |
| 17 | Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer显示文摘Objective:Real-word data on long-acting luteinizing hormone-releasing hormone(LHRH)agonists in Chinese patients with prostate cancer are limited.This study aimed to determine the real-world effectiveness and safety of the LHRH agonist,goserelin,particularly the long-acting 10.8-mg depot formulation,and the follow-up patterns among Chinese prostate cancer patients.Methods:This was a multicenter,prospective,observational study in hormone treatment-na?ve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen.The patients had follow-up evaluations for 26 weeks.The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen(PSA)levels.The secondary outcomes included testosterone and PSA levels,attainment of chemical castration(serum testosterone<50 ng/d L),and goserelin safety.The exploratory outcome was the monitoring pattern for serum testosterone and PSA.All analyses were descriptive.Results:Between September 2017 and December 2019,a total of 294 eligible patients received≥1 dose of goserelin;287 patients(97.6%)were treated with goserelin 10.8-mg depot.At week 24±2,the changes from baseline[standard deviation(95%confidence interval)]in serum testosterone(n=99)and PSA(n=131)were-401.0 ng/d L[308.4 ng/d L(-462.5,-339.5 ng/d L)]and-35.4 ng/m L[104.4 ng/m L(-53.5,-17.4 ng/m L)],respectively.Of 112 evaluable patients,100(90.2%)achieved a serum testosterone level<50 ng/d L.Treatment-emergent adverse events(TEAEs)and severe TEAEs occurred in 37.1%and 10.2%of patients,respectively.The mean testing frequency(standard deviation)was 1.6(1.5)for testosterone and 2.2(1.6)for PSA.Conclusions:Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer. | Nanhui Chen Zengjun Wang Ming Chen Qi Ma Yi He Yujie Wang Xin Li Mingxing Qiu Lei Shi Shaoxing Zhu Qun Xie Xiuheng Liu Benkang Shi Guowen Lin Weizhong Yang Yongbin Liao Haibin Zhang Shusheng Wang Jiexian Li Shaogang Wang Lijun Dong Hui Chen Jiaju Lu YongyiCheng Xiaoping Zhang Lulin Ma Liqun Zhou He Wang Shen Li Dingwei Ye | 2023 | Cancer Biology & Medicine2023，20，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员